WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317851
CAS#: 86-35-1
Description: Ethotoin is an anticonvulsant drug used in the treatment of epilepsy. It is a hydantoin, similar to phenytoin. Ethotoin lacks phenytoin's side effects of gingival hyperplasia and hirsutism; however, it is less effective. This, combined with the need for frequent dosing has limited its usefulness. Ethotoin is no longer widely used.
Hodoodo Cat#: H317851
Name: Ethotoin
CAS#: 86-35-1
Chemical Formula: C11H12N2O2
Exact Mass: 204.09
Molecular Weight: 204.225
Elemental Analysis: C, 64.69; H, 5.92; N, 13.72; O, 15.67
Synonym: Ethotoin, Peganone.
IUPAC/Chemical Name: 3-Ethyl-5-phenyl-2,4-Imidazolidinedione
InChi Key: SZQIFWWUIBRPBZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)
SMILES Code: O=C1N(CC)C(C(C2=CC=CC=C2)N1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 204.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Hooper WD, O'Shea NJ, Qing MS. Enantioselective pharmacokinetics of ethotoin in humans following single oral doses of the racemate. Chirality. 1992;4(3):142-7. PubMed PMID: 1350205.
2: Minck DR, Acuff-Smith KD, Vorhees CV. Comparison of the behavioral teratogenic potential of phenytoin, mephenytoin, ethotoin, and hydantoin in rats. Teratology. 1991 Apr;43(4):279-93. PubMed PMID: 1675495.
3: Biton V, Gates JR, Ritter FJ, Loewenson RB. Adjunctive therapy for intractable epilepsy with ethotoin. Epilepsia. 1990 Jul-Aug;31(4):433-7. PubMed PMID: 1973383.
4: Browne TR, Szabo GK. A pharmacokinetic rationale for three times daily administration of ethotoin (Peganone). J Clin Pharmacol. 1989 Mar;29(3):270-1. PubMed PMID: 2566627.
5: Inotsume N, Fujii J, Honda M, Nakano M, Higashi A, Matsuda I. Stereoselective analysis of the enantiomers of ethotoin in human serum using chiral stationary phase liquid chromatography and gas chromatography-mass spectrometry. J Chromatogr. 1988 Jul 15;428(2):402-7. PubMed PMID: 2905704.
6: Inotsume N, Higashi A, Kinoshita E, Matsuoka T, Nakano M. Rapid and sensitive determination of ethotoin as well as carbamazepine, phenobarbital, phenytoin and primidone in human serum. J Chromatogr. 1986 Nov 28;383(1):166-71. PubMed PMID: 2880855.
7: Carter CA, Helms RA, Boehm R. Ethotoin in seizures of childhood and adolescence. Neurology. 1984 Jun;34(6):791-5. PubMed PMID: 6145119.
8: Meyer MC, Holcombe BJ, Burckart GJ, Raghow G, Yau MK. Nonlinear ethotoin kinetics. Clin Pharmacol Ther. 1983 Mar;33(3):329-34. PubMed PMID: 6130866.
9: Korberly BH, Mrazik TJ, Graziani LJ. Ethotoin use in pediatric seizure patients. Am J Dis Child. 1981 Dec;135(12):1139-40. PubMed PMID: 6119023.
10: Bius DL, Yonekawa WD, Kupferberg HJ, Cantor F, Dudley KH. Gas chromatographic-mass spectrometric studies on the metabolic fate of ethotoin in man. Drug Metab Dispos. 1980 Jul-Aug;8(4):223-9. PubMed PMID: 6105055.
11: Troupin AS, Friel P, Lovely MP, Wilensky AJ. Clinical pharmacology of mephenytoin and ethotoin. Ann Neurol. 1979 Nov;6(5):410-4. PubMed PMID: 42344.
12: Geneidi AS, Ali AA, Salama RB. Solid dispersions of nitrofurantoin, ethotoin, and coumarin with polyethylene glycol 6000 and their coprecipitates with providone 25,000. J Pharm Sci. 1978 Jan;67(1):114-6. PubMed PMID: 22737.
13: Zablen M, Brand N. Cleft lip and palate with the anticonvulsant ethotoin. N Engl J Med. 1977 Dec 22;297(25):1404. PubMed PMID: 22040.
14: Naestoft J, Larsen NE. Mass fragmentographic quantitation of ethotoin and some of its metabolites in human urine. J Chromatogr. 1977 Mar 1;143(2):161-9. PubMed PMID: 14171.
15: Naestoft J, Hvidberg EF, Sjö O. Saturable metabolic pathways for ethotoin in man. Clin Exp Pharmacol Physiol. 1976 Sep-Oct;3(5):453-9. PubMed PMID: 10117.
16: Dudley KH, Bius DL. Buffer catalysis of the racemization reaction of some 5-phenylhydantoins and its relation to the in vivo metabolism of ethotoin. Drug Metab Dispos. 1976 Jul-Aug;4(4):340-8. PubMed PMID: 8288.
17: Sjö, Hvidberg EF, Larsen NE, Naestoft J. Dose-dependent kinetics of ethotoin in man. Clin Exp Pharmacol Physiol. 1975 May-Jun;2(3):185-92. PubMed PMID: 238776.
18: Dudley KH, Bius DL, Butler TC. Metabolic fates of 3-ethyl-5-phenylhydantoin (ethotoin, peganone), 3-methyl-5-phenylhydantoin and 5-phenylhydantoin. J Pharmacol Exp Ther. 1970 Oct;175(1):27-37. PubMed PMID: 5471450.
19: GRUBER CM Jr, BROCK JT, DYKEN M. Comparison of the effectiveness of phenobarital, mephobarbital, primidone, diphenylhydantoin, ethotoin, metharbital, and methylphenylethylhydantoin in motor seizures. Clin Pharmacol Ther. 1962 Jan-Feb;3:23-8. PubMed PMID: 13902356.
20: SALTZSTEIN SL, JAUDON JC, LUSE SA, ACKERMAN LV. Lymphadenopathy induced by ethotoin (peganone); clinical and pathological mimicking of malignant lymphoma. J Am Med Assoc. 1958 Jul 26;167(13):1618-20. PubMed PMID: 13563153.
